The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase III study of etoposide plus cisplatin versus irinotecan plus cisplatin in advanced neuroendocrine carcinoma of the digestive system: A Japan Clinical Oncology Group study (JCOG1213).
 
Chigusa Morizane
Honoraria - Lilly; Novartis; Pfizer; Yakult Honsha
Consulting or Advisory Role - AstraZeneca; Novartis; Yakult Honsha
Research Funding - GlaxoSmithKline (Inst); Nobelpharma (Inst); Pfizer (Inst)
 
Nozomu Machida
No Relationships to Disclose
 
Yoshitaka Honma
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); Merck Serono (Inst); NanoCarrier (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Teijin Pharma (Inst)
 
Takuji Okusaka
Honoraria - Bayer Yakuhin; Chugai Pharma; Dainippon Sumitomo Pharma; Eisai; Lilly; Merck Serono; Novartis; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; Chugai Pharma; Dainippon Sumitomo Pharma; Lilly; NanoCarrier; Nippon Boehringer Ingelheim; Nobelpharma; Novartis; OncoTherapy Science; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha; Zeria Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer Yakuhin (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Kowa (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); Sceti Medical Labo (Inst); Shizuoka (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Narikazu Boku
Honoraria - Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Shionogi
Research Funding - Chugai Pharma (Inst); Taiho Pharmaceutical (Inst)
 
Ken Kato
Honoraria - Bristol-Myers Squibb; Dainippon Sumitomo Pharma; Lilly; Nippon Kayaku; Pfizer; Sanofi; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Lilly (Inst); Merck Serono (Inst); NanoCarrier (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Teijin Pharma (Inst)
 
Junki Mizusawa
Honoraria - Chugai Pharma
 
Hiroshi Katayama
No Relationships to Disclose
 
Nobuyoshi Hiraoka
No Relationships to Disclose
 
Hirokazu Taniguchi
No Relationships to Disclose
 
Masafumi Ikeda
Consulting or Advisory Role - NanoCarrier
Speakers' Bureau - Abbott Diagnostics; Bayer Yakuhin; Bristol-Myers Squibb; Dainippon Sumitomo Pharma; Guerbet; Kyowa Hakko Kirin; Merck Serono; Novartis; Takeda; Yakult Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer Yakuhin (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Kowa (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Yakult Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)
 
Yuichi Shibuya
No Relationships to Disclose
 
Ayumu Hosokawa
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Taiho Pharmaceutical; Takeda; Tsumura & Co.; Yakult Honsha
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Taiho Pharmaceutical (Inst)
 
Nobumasa Mizuno
Honoraria - Novartis; Pfizer
 
Takeshi Sano
No Relationships to Disclose
 
Masahiro Tsuda
No Relationships to Disclose
 
Osamu Yokosuka
Research Funding - Bayer (Inst); Chugai Pharma (Inst); MSD (Inst)
 
Yuko Kitagawa
No Relationships to Disclose
 
Mitsuru Sasako
Honoraria - Chugai Pharma; Lilly; Taiho Pharmaceutical
 
Junji Furuse
Honoraria - Ajinomoto; Astellas Pharma; Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Eisai; Hisamitsu Pharmaceutical; Kyowa Hakko Kirin; Lilly; Meiji Seika Kaisha; Merck Serono; Mitsubishi Tanabe Pharma; Nippon Kayaku; Ono Pharmaceutical; Sandoz; Sanofi; Shionogi; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Chugai Pharma; Eisai; Fujifilm; GlaxoSmithKline; J-Pharma; Janssen; Kowa; Kyowa Hakko Kirin; Merck Serono; Otsuka; Yakult Pharmaceutical; Zeria Pharmaceutical
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Merck Serono (Inst); Nippon Kayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Torii Pharmaceutical (Inst); Yakult Pharmaceutical (Inst)